Equillium, Inc. (EQ) Stock Price & Analysis
Equillium, Inc. (EQ) closed at USD 1.32 on Thursday, October 15, 2026, up 1.54% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.3; the Oct 15, 2026 session ranged USD 1.28–1.38 on volume of 510,931 shares. Market capitalization is $83.70M, with a 52-week range of USD 0.76–3.54 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EQ.md
Key facts (EQ)
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 8.56 (range 4–20).
- Total return with dividends: 1Y +7.3% vs S&P 500 +18.1%; 5Y -77.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.05, revenue estimate $0K.
Analysts (EQ)
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 8.56 (low 4, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-04 | Roth Capital | Reiterated | Buy | $12 |
| 2026-07-13 | Piper Sandler | Initiated | Overweight | $20 |
Total return (dividends reinvested) (EQ)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +7.3% | -77.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +7.3% | -25.9% |
| Volatility (annualized) | 104.0% | 109.1% |
| Max drawdown | -59.4% (Jun 2026→Oct 2026) | -95.2% (Nov 2021→Jun 2025) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 1.32 |
|---|---|
| Change | ▲ 1.54% (up) |
| Previous Close | USD 1.3 |
| Open | USD 1.3 |
| Day Range | USD 1.28 – 1.38 |
| 52-Week Range | USD 0.76 – 3.54 |
| Volume | 510,931 shares |
| Market Cap | $83.70M |
| Exchange | NCM |
Technical Analysis (EQ)
Nexqual's technical model rates EQ "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.82 (oversold) |
| vs SMA50 | Below (USD 1.97) |
| MACD | -0.2 (negative) |
Analyst Ratings (EQ)
Wall Street analysts rate EQ "Buy" based on 9 analysts, with a mean price target of USD 8.56 (range USD 4–20), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 8.56 |
| High Target | USD 20 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (EQ)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.04 vs est -0.06 ▲ beat |
| 2026-03-31 | USD -0.06 vs est -0.04 ▼ miss |
| 2025-12-31 | USD -0.04 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.06 vs est -0.22 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (EQ)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -58.98% |
| Debt / Equity | 0.01 |
| Current Ratio | 23.4 |
| Total Cash | $57.16M |
| Total Debt | $584,000 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (EQ)
Nexqual rates Equillium, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $57M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M (TTM) |
| Efficiency | Critical — ROE -59%, ROA -34.0% |
Ownership (EQ)
| Insider Ownership | +16.00% |
|---|---|
| Institutional Ownership | +65.76% |
| Shares Outstanding | 63.41M |
| Float | 36.97M |
| Short % of Float | +10.13% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (EQ)
Equillium, Inc. is led by Bruce Steel (age 59), Co-Founder, CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| Co-Founder, CEO & Director | Bruce Steel (age 59) |
|---|---|
| Chief Scientific Officer & President | Stephen Connelly (age 44) |
| Senior VP & COO | Christine Zedelmayer M.B.A., P.M.P. (age 55) |
| Vice President of Investor Relations & Corporate Communications | Michael Moore |
| Vice President of Clinical Development | Lisette Acevedo |
Major Backers & Investors (EQ)
Notable institutional backers of Equillium, Inc. include Jupiter Topco LLC, Decheng Capital LLC, Affinity Asset Advisors, Llc, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 10.24% |
| Decheng Capital LLC | 7.01% |
| Affinity Asset Advisors, Llc | 6.47% |
| Adar1 Capital Management, LLC | 5.93% |
| Aberdeen Group plc | 5.73% |
| abrdn Life Sciences Investors | 5.73% |
| Woodline Partners LP | 5.52% |
| RA Capital Management, L.P. | 4.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.62% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt